Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: Results of a randomized trial
Journal of Infectious Diseases, Volume 197, No. 10, Year 2008
Notification
URL copied to clipboard!
Description
Background. Vaginal infections are common and have been associated with increased risk for acquisition of human immunodeficiency virus type 1 (HIV-1). Methods. We conducted a randomized trial of directly observed oral treatment administered monthly to reduce vaginal infections among Kenyan women at risk for HIV-1 acquisition. A trial intervention of 2 g of metronidazole plus 150 mg of fluconazole was compared with metronidazole placebo plus fluconazole placebo. The primary end points were bacterial vaginosis (BV), vaginal candidiasis, trichomoniasis vaginalis (hereafter, "trichomoniasis"), and colonization with Lactobacillus organisms. Results. Of 310 HIV-1-seronegative female sex workers enrolled (155 per arm), 303 were included in the primary end points analysis. A median of 12 follow-up visits per subject were recorded in both study arms (P = .8). Compared with control subjects, women receiving the intervention had fewer episodes of BV (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.49-0.63) and more frequent vaginal colonization with any Lactobacillus species (HR, 1.47; 95% CI, 1.19 -1.80) and H2O 2-producing Lactobacillus species (HR, 1.63; 95% CI, 1.16 -2.27). The incidences of vaginal candidiasis (HR, 0.84; 95% CI, 0.67-1.04) and trichomoniasis (HR, 0.55; 95% CI, 0.27-1.12) among treated women were less than those among control subjects, but the differences were not statistically significant. Conclusions. Periodic presumptive treatment reduced the incidence of BV and promoted colonization with normal vaginal flora. Vaginal health interventions have the potential to provide simple, female-controlled approaches for reducing the risk of HIV-1 acquisition. © 2008 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
McClelland, Raymond Scott
United States, Seattle
University of Washington
Kenya, Nairobi
University of Nairobi
Richardson, Barbra Ann
United States, Seattle
University of Washington
Hassan, Wisal M.
United States, Seattle
University of Washington
Chohan, Vrasha
Kenya, Nairobi
University of Nairobi
Lavreys, Ludo
United States, Seattle
University of Washington
Kenya, Nairobi
University of Nairobi
Mandaliya, Kishor N.
Kenya, Mombasa
Coast Provincial General Hospital, Kenya
Kiarie, James Njogu
Kenya, Nairobi
University of Nairobi
Jaoko, Walter G.
Kenya, Nairobi
University of Nairobi
Ndinya-Achola, Jeckoniah O.
Kenya, Nairobi
University of Nairobi
Baeten, Jared M.
United States, Seattle
University of Washington
Kurth, Ann Elizabeth
United States, Seattle
University of Washington
Holmes, King K.
United States, Seattle
University of Washington
Statistics
Citations: 93
Authors: 12
Affiliations: 3
Identifiers
Doi:
10.1086/587490
ISSN:
00221899
Research Areas
Environmental
Health System And Policy
Infectious Diseases
Study Design
Randomised Control Trial
Cohort Study
Participants Gender
Female